Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

NRG-BR002 Shows No PFS Benefit for Ablation in Oligometastatic Breast Cancer

NRG-BR002 found no progression-free or overall survival advantage for metastasis-directed ablation added to first-line systemic therapy in oligometastatic breast cancer.

By Dr. Revathy Mohan V.R., MBBS · Oct 23, 2026 · 5 min read

Oncology·JCO

Neuroblastoma Telomere Maintenance Improves Risk Stratification

Telomere maintenance mechanisms outperformed standard molecular classifiers in neuroblastoma risk assessment across test and validation cohorts.

Oct 23, 2026

Oncology·JCO

Varegacestat cuts desmoid tumor volume in RINGSIDE phase II trial

RINGSIDE phase II showed varegacestat reduced desmoid tumor volume with manageable toxicity, supporting selection of the 1.2-mg daily…

Oct 23, 2026

Oncology·JCO

Melanoma transcriptomic states predict response to immunotherapy combinations

A large melanoma multi-omics analysis separates two ICB-resistant states and links transcriptomic biology to response patterns with BRAF/MEK…

Oct 23, 2026

Oncology·JCO

Facilitated BRCA1/2 Cascade Testing Boosts Relatives’ Uptake in Randomized Trial

Facilitated cascade genetic testing raised BRCA1/2 testing uptake among first-degree relatives, with higher completion and frequent detection of…

Oct 23, 2026

Oncology·JCO

Sentinel Lymph Node Biopsy After NAC in Locally Advanced Breast Cancer

Prospective JCO study examines sentinel node biopsy after neoadjuvant chemotherapy in cT4 or cN2/N3 breast cancer with axillary…

Oct 23, 2026

Oncology·JCO

Retlirafusp Alfa Improves Survival in First-Line Gastric Cancer

RELIGHT showed retlirafusp alfa plus CAPOX improved overall and progression-free survival in HER2-negative gastric or GEJ adenocarcinoma.

Oct 23, 2026

Oncology·JCO

Daratumumab-Quadruplet Improves PFS in Transplant-Ineligible Myeloma

CEPHEUS subgroup data show daratumumab-VRd deepened MRD negativity and prolonged PFS in transplant-ineligible newly diagnosed multiple myeloma.

Oct 23, 2026

Oncology·JCO

Ambient AI Scribes in Oncology and Documentation Burden

A JCO/ASCO abstract examines ambient artificial intelligence scribes in oncology, focusing on clinician experience and documentation burden.

Oct 23, 2026

Oncology·JCO

Meilian Fuxin liquid studied for radiation-induced oral mucositis in head and neck cancer

ASCO/JCO abstract examines Meilian Fuxin liquid for radiation-induced oral mucositis in head and neck cancer, where pain and…

Oct 23, 2026

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.